305 related articles for article (PubMed ID: 30624037)
1. Critical Features for Mesoporous Silica Nanoparticles Encapsulated into Erythrocytes.
Chen ZA; Wu SH; Chen P; Chen YP; Mou CY
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4790-4798. PubMed ID: 30624037
[TBL] [Abstract][Full Text] [Related]
2. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
3. Redox-responsive mesoporous silica as carriers for controlled drug delivery: a comparative study based on silica and PEG gatekeepers.
Wang Y; Han N; Zhao Q; Bai L; Li J; Jiang T; Wang S
Eur J Pharm Sci; 2015 May; 72():12-20. PubMed ID: 25701727
[TBL] [Abstract][Full Text] [Related]
4. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses.
He Q; Zhang J; Shi J; Zhu Z; Zhang L; Bu W; Guo L; Chen Y
Biomaterials; 2010 Feb; 31(6):1085-92. PubMed ID: 19880176
[TBL] [Abstract][Full Text] [Related]
5. Peptide-laden mesoporous silica nanoparticles with promoted bioactivity and osteo-differentiation ability for bone tissue engineering.
Luo Z; Deng Y; Zhang R; Wang M; Bai Y; Zhao Q; Lyu Y; Wei J; Wei S
Colloids Surf B Biointerfaces; 2015 Jul; 131():73-82. PubMed ID: 25969416
[TBL] [Abstract][Full Text] [Related]
6. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects.
Zhao Y; Sun X; Zhang G; Trewyn BG; Slowing II; Lin VS
ACS Nano; 2011 Feb; 5(2):1366-75. PubMed ID: 21294526
[TBL] [Abstract][Full Text] [Related]
7. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.
He Q; Zhang Z; Gao F; Li Y; Shi J
Small; 2011 Jan; 7(2):271-80. PubMed ID: 21213393
[TBL] [Abstract][Full Text] [Related]
8. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
[TBL] [Abstract][Full Text] [Related]
9. PEGylated Lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect.
Lin J; Cai Q; Tang Y; Xu Y; Wang Q; Li T; Xu H; Wang S; Fan K; Liu Z; Jin Y; Lin D
Int J Pharm; 2018 Jan; 536(1):272-282. PubMed ID: 29079221
[TBL] [Abstract][Full Text] [Related]
10. Mimicking red blood cell lipid membrane to enhance the hemocompatibility of large-pore mesoporous silica.
Roggers RA; Joglekar M; Valenstein JS; Trewyn BG
ACS Appl Mater Interfaces; 2014 Feb; 6(3):1675-81. PubMed ID: 24417657
[TBL] [Abstract][Full Text] [Related]
11. A mesoporous silica nanoparticle with charge-convertible pore walls for efficient intracellular protein delivery.
Park HS; Kim CW; Lee HJ; Choi JH; Lee SG; Yun YP; Kwon IC; Lee SJ; Jeong SY; Lee SC
Nanotechnology; 2010 Jun; 21(22):225101. PubMed ID: 20453291
[TBL] [Abstract][Full Text] [Related]
12. High-throughput 3D visualization of nanoparticles attached to the surface of red blood cells.
Dias A; Werner M; Ward KR; Fleury JB; Baulin VA
Nanoscale; 2019 Jan; 11(5):2282-2288. PubMed ID: 30657510
[TBL] [Abstract][Full Text] [Related]
13. Lipid bilayer-coated mesoporous silica nanoparticles carrying bovine hemoglobin towards an erythrocyte mimic.
Tu J; Bussmann J; Du G; Gao Y; Bouwstra JA; Kros A
Int J Pharm; 2018 May; 543(1-2):169-178. PubMed ID: 29567198
[TBL] [Abstract][Full Text] [Related]
14. Fluorescent carbon dot modified mesoporous silica nanocarriers for redox-responsive controlled drug delivery and bioimaging.
Jiao J; Liu C; Li X; Liu J; Di D; Zhang Y; Zhao Q; Wang S
J Colloid Interface Sci; 2016 Dec; 483():343-352. PubMed ID: 27569517
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica nanoparticles capped with disulfide-linked PEG gatekeepers for glutathione-mediated controlled release.
Cui Y; Dong H; Cai X; Wang D; Li Y
ACS Appl Mater Interfaces; 2012 Jun; 4(6):3177-83. PubMed ID: 22646097
[TBL] [Abstract][Full Text] [Related]
16. Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy.
Ma'mani L; Nikzad S; Kheiri-Manjili H; Al-Musawi S; Saeedi M; Askarlou S; Foroumadi A; Shafiee A
Eur J Med Chem; 2014 Aug; 83():646-54. PubMed ID: 25014638
[TBL] [Abstract][Full Text] [Related]
17. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
[TBL] [Abstract][Full Text] [Related]
18. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.
Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C
J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602
[TBL] [Abstract][Full Text] [Related]
19. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
20. Extra-Large Pore Mesoporous Silica Nanoparticles for Directing in Vivo M2 Macrophage Polarization by Delivering IL-4.
Kwon D; Cha BG; Cho Y; Min J; Park EB; Kang SJ; Kim J
Nano Lett; 2017 May; 17(5):2747-2756. PubMed ID: 28422506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
